Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Jan 2, 2014)
  • 8-K (Nov 12, 2013)
  • 8-K (Nov 7, 2013)
  • 8-K (Aug 6, 2013)
  • 8-K (Jul 9, 2013)
  • 8-K (Jun 24, 2013)

 
Other

Santarus 8-K 2005

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Ex-99.1
Santarus, Inc. (Form: 8-K)  

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   July 26, 2005

Santarus, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-50651 33-0734433
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
10590 West Ocean Air Drive, Suite 200, San Diego, California   92130
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   (858) 314-5700

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01 Other Events.

On July 26, 2005, Santarus, Inc. announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing its New Drug Application ("NDA") for ZEGERID® (omeprazole) Chewable Tablets 40 mg and 20 mg. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Santarus expects the FDA will complete its review or otherwise respond to the ZEGERID Chewable Tablets NDA by March 26, 2006. A press release announcing the acceptance for filing of the NDA is attached to this report as Exhibit 99.1 and incorporated herein by reference.





Item 9.01 Financial Statements and Exhibits.

99.1 -- Press Release dated July 26, 2005






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Santarus, Inc.
          
July 26, 2005   By:   Debra P. Crawford
       
        Name: Debra P. Crawford
        Title: Senior Vice President, Chief Financial Officer, Treasurer and Secretary


Exhibit Index


     
Exhibit No.   Description

 
99.1
  Press Release dated July 26, 2005
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki